Radiation after surgery for lung cancer that spread to lymph nodes
Part of Cancer, Lungs & breathing clinical trials.
This trial tests if giving radiation after surgery can help people with non-small cell lung cancer that has spread to multiple lymph nodes in the chest. It may offer a treatment option for those who have not had chemotherapy or immunotherapy before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have non-small cell lung cancer that spread to at least 3 lymph nodes in the chest after surgery.
- You have not had radiation, chemotherapy, or immunotherapy before.
- You are in reasonably good health and can take care of yourself (ECOG 0-2).
- Your major organs like bone marrow, liver, and kidneys are working well.
- You do not have an active autoimmune disease or condition that weakens your immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether giving radiation therapy after surgery can help prevent lung cancer from coming back in people who have already had chemotherapy and immunotherapy before surgery. It is for patients whose cancer had spread to chest lymph nodes and who still have some cancer left in those nodes after surgery.
This trial tests a combination of radiation, an immunotherapy drug called tislelizumab, and chemotherapy given before surgery for non-small cell lung cancer that has not spread too far (stage II-III). The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests whether giving focused radiation to remaining spots of lung cancer (after standard treatment) can help prevent cancer from growing back. It may be an option if you have had 4-6 cycles of chemo plus immunotherapy and still have a few active spots.
This trial tests a combination of immunotherapy (tislelizumab), a targeted therapy (anlotinib), and standard chemotherapy before and after surgery for people with early-stage but high-risk lung cancer. The goal is to see if this treatment shrinks the tumor, makes surgery more effective, and helps prevent the cancer from coming back.
This trial tests a combination of radiation therapy before surgery, followed by the immunotherapy drug tislelizumab and the targeted therapy drug anlotinib after surgery, for people with stage II to IIIA non-small cell lung cancer (NSCLC). The goal is to see if this approach can improve outcomes for patients whose tumors can be removed surgically.
This trial tests combining the immunotherapy drug tislelizumab with radiation therapy for people with advanced non-squamous non-small cell lung cancer that hasn't been treated before. It aims to see if this combination helps control the cancer better than standard treatments.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.